Journal article
Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 59.5KB)
-
- Publisher copy:
- 10.1016/s1470-2045(18)30753-8
Authors
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Lancet Oncology Journal website
- Volume:
- 19
- Issue:
- 11
- Pages:
- 1424-1426
- Publication date:
- 2018-10-22
- Acceptance date:
- 2018-10-05
- DOI:
- EISSN:
-
1474-5488
- ISSN:
-
1470-2045
- Pmid:
-
30361171
- Source identifiers:
-
935907
Item Description
- Language:
- English
- Pubs id:
-
pubs:935907
- UUID:
-
uuid:31259d98-108d-4b60-8d12-060c7eb96e1a
- Local pid:
- pubs:935907
- Deposit date:
- 2018-12-19
Terms of use
- Copyright holder:
- Elsevier
- Copyright date:
- 2018
- Notes:
- © 2018 Elsevier Ltd. All rights reserved. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/S1470-2045(18)30753-8
If you are the owner of this record, you can report an update to it here: Report update to this record